

## **The Royal Free London (RFL) NHS Foundation Trust, National Amyloidosis Centre (NAC) and Pfizer UK (Pfizer) Collaborative Working Project: Accelerated clinical review of the patients already diagnosed with cardiac amyloidosis (CA).**

### **Background:**

CA is a progressive infiltrative heart muscle disease, caused by the accumulation of insoluble amyloid fibrils in the heart muscle (myocardium). The resulting cardiomyopathy eventually progresses to end-stage heart failure. Life expectancy without access to specialised treatment is poor.

### **Project:**

The objective of the project is to improve the care of patients with CA by accelerating the clinical review and optimisation of treatment, for patients with a confirmed diagnosis of CA, as assessed by an expert clinician at the NAC.

The project will run over a total of 12 months:

- To incorporate an initial 6-month period to triage and initiate appropriate treatment for eligible patients who are already diagnosed with CA.
- This will be followed by a 6-month period to establish best working practices for ongoing management of these patients.

### **Benefits:**

#### **1. Benefits to Patients**

- Improved access to expert review and specialised medicines and treatments
- Specialist Healthcare support from National Amyloidosis Centre.
- Improved adherence to medicines through specialist nurse support.
- Improved outcomes for amyloid patients (e.g., improve decision making by specialist multi-disciplinary team (MDT), access to expert diagnostics and experience in treatment decision making, direct links to NAC).

#### **2. Benefits to NHS**

- Efficiency in NAC working practice to review patients in an accelerated manner reducing impact on wider NHS organisations.
- Maintain current NAC waiting times despite an increased number of patients requiring review.
- Sharing of best clinical practice across a future amyloid network.

#### **3. Benefits to Pfizer**

Date of prep: July 2024

Job Bag No: PP-UNP-GBR-9618

- The project will result in the identification of patients who are eligible for appropriate treatment.
- Expected increase in the speed of uptake of licensed treatment for eligible patients.
- Increase understanding of service provision.

**Outcomes:**

To deliver an accelerated clinical review of patients already diagnosed with cardiac amyloidosis (CA) and to establish best working practices for ongoing treatment.

Proposed term of the Collaborative Working Project:

Start date: 2<sup>nd</sup> September 2024

End date: 1<sup>st</sup> September 2025

**Financial Arrangement:**

*The National Amyloidosis Centre will contribute:*

*Diagnostic support: £65,100.00*

*Human resource support: 1,894 hours*

*Pfizer UK Ltd will contribute:*

*Clinical Nurse Specialist and Data administration funding: £110,608.00*

*Human resource: 540 hours*